Bessemer Group
TARS icon

Bessemer Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Bessemer Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4K Buy
59
+11
+23% +$703 ﹤0.01% 2326
2026
Q1 		$3K Hold
48
– – ﹤0.01% 2333
2025
Q4 		$4K Hold
48
– – ﹤0.01% 2302
2025
Q3 		$3K Buy
+48
New +$2.36K ﹤0.01% 2267

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bessemer Group's TARS Position: Q2 2026 in Review

Bessemer Group increased its Tarsus Pharmaceuticals (TARS) stake by 23% in Q2 2026, buying an estimated $703 and bringing the position to 59 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

Bessemer Group first reported a position in TARS in Q3 2025 and has held it in 4 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Bessemer Group held 59 shares of Tarsus Pharmaceuticals worth $4K as of Q2 2026.
  • Bessemer Group bought 11 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $703.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2326 holding.
  • Bessemer Group first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.